Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
van Kempen ZLE, Wieske L, Stalman EW, Kummer LYL, van Dam PJ, Volkers AG, Boekel L, Toorop AA, Strijbis EMM, Tas SW, Wolbink GJ, Löwenberg M, van Sandt C, Ten Brinke A, Verstegen NJM, Steenhuis M, Kuijpers TW, van Ham SM, Rispens T, Eftimov F, Killestein J; T2B! immunity against SARS-CoV-2 study group. van Kempen ZLE, et al. Mult Scler Relat Disord. 2022 Jan;57:103416. doi: 10.1016/j.msard.2021.103416. Epub 2021 Nov 23. Mult Scler Relat Disord. 2022. PMID: 34847379 Free PMC article.
The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.
Toorop AA, van Lierop ZYGJ, Strijbis EMM, Teunissen CE, Barkhof F, Uitdehaag BMJ, van Kempen ZLE, Killestein J. Toorop AA, et al. Mult Scler Relat Disord. 2022 Jan;57:103364. doi: 10.1016/j.msard.2021.103364. Epub 2021 Nov 1. Mult Scler Relat Disord. 2022. PMID: 35158470 Free article.
Natalizumab discontinuation in a Dutch real-world cohort.
Coerver EME, Wessels MHJ, van Lierop ZYG, van Kempen ZLE, Killestein J, Strijbis EMM. Coerver EME, et al. Mult Scler Relat Disord. 2021 Jul;52:102974. doi: 10.1016/j.msard.2021.102974. Epub 2021 Apr 24. Mult Scler Relat Disord. 2021. PMID: 33990055
82 results